Term
| Cisplatin/Carboplatin/Paraplatin MOA |
|
Definition
similar to alkylating agents, so often classified with them; forms platinum complexes at N7 of guanine and forms inter- and intrastrand cross-links. The resulting cytotoxic lesion inhibits both DNA replication and RNA synthesis. Cells are most vulnerable in G1 and S phases |
|
|
Term
| Cisplatin/Carboplatin/Paraplatin Resistance Mechanisms |
|
Definition
| elevated glutathione or increased DNA repair or decreased cellular uptake; increased levels of metallothionein bind to and inactivate both drugs |
|
|
Term
| Vinblastine and Vincristine MOA |
|
Definition
| block polymerization of microtubules, preventing cell division |
|
|
Term
| Taxane/Paclitaxel/Docetaxel MOA |
|
Definition
stabilize microtubules and prevent depolymerization |
|
|
Term
| Paclitaxel/Docetaxel Side Effects |
|
Definition
| Neuropathy is the dose limiting factor. |
|
|
Term
| Paclitaxel/Docetaxel Drug Interactions |
|
Definition
carboplatin/cisplatin for increased risk of neuropathy |
|
|
Term
| Levamisole Buzz Words for question stem |
|
Definition
crack cocaine
Ascaris/de-worming
skin lesions/necrosis |
|
|
Term
|
Definition
| Not positive of the MOA, but thought to be immunomodulatory by stimulating NK cells and T-cells |
|
|
Term
|
Definition
| FDUMP inhibits thymdylate synthetase, causing DNA damage and cell death |
|
|
Term
|
Definition
| Metronidazole due to decreased clearance of 5-FU |
|
|
Term
|
Definition
| Monoclonal antibody that binds the external domain of HER2/neu, a receptor that is greatly amplified in cancer cells |
|
|
Term
|
Definition
| Cardiotoxicity is the dose limiting factor. |
|
|
Term
| Monoclonal Antibody Resistance Mechanisms |
|
Definition
1. therapeutic agent can't recognize target
2. compensatory signaling causing upregulation of other HER receptors or another family of receptors
3. altered downstream signaling
4. competition for binding therapeutic agent |
|
|
Term
| Gastric Adenocarcinoma Treatment |
|
Definition
Cisplatin with epirubicin or docetaxel
or
5-FU with irinotecan |
|
|
Term
|
Definition
| Stabilizes the cleavable complex of Topoisomerase binding to DNA, causing a double-stranded DNA break |
|
|
Term
|
Definition
treat with a PPI and antibiotic series
|
|
|
Term
| Eradication of H. pylori often cures |
|
Definition
| MALToma/low grade B cell lymphoma |
|
|
Term
| Treatment of B cell lymphoma if there is chromosomal abnormality preventing cure by eradication of H. pylori |
|
Definition
Cyclophosphamide
Hydroxydaunorubicin (doxorubicin)
Oncovin (Vincristine)
Prednisone
+ rituximab
CHOP + rituximab |
|
|
Term
|
Definition
|
|
Term
|
Definition
| CD20 monoclonal antibody that makes cell susceptible NK cells |
|
|
Term
| Doxorubicin Dose-Limiting Effect |
|
Definition
| cardiotoxicity, cumulative effect |
|
|
Term
| Treatment of Pancreatic Cancer |
|
Definition
| Single agent therapy of Gemcitabine |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Single agent therapy of Imatinib |
|
|
Term
|
Definition
tyrosine kinase inhibitor
inhibits the c-Kit pathway |
|
|
Term
| Why does concomitant use of leucovorin with 5-FU improve its efficacy? |
|
Definition
| Increases efficacy of 5-FU by stabilizing the binding of FDUMP to thymidylate synthetase |
|
|
Term
| Treatment of Metastatic Colorectal Cancer |
|
Definition
FOL = Leucovorin (folinic acid)
F = 5-FU
OX = oxaliplatin
or
FOL
F
IRI = irinotecan |
|
|
Term
In treating colorectal cancer, and
appear to have therapeutic synergy with irinotecan even in patients previously resistant to the drug. |
|
Definition
| cetuximab and panitumumab |
|
|
Term
| Cetuximab and panitumumab are not effective in colon tumors with mutations. and other tyrosine kinase inhibitors do not appear to be effective |
|
Definition
|
|
Term
| therapy with concomitant chemotherapy has resulted in biopys proven disappearance of all anal cancer tumors in >80% of patients whose initial leasion was <3 cm in size. |
|
Definition
|
|
Term
| Most often used chemotherapeutics in treatment of anal cancer |
|
Definition
| combo of 5-FU and mitomycin |
|
|
Term
| Rate limitation of external bean radiation therapy for anal cancer |
|
Definition
| pelvic fractures in women |
|
|
Term
|
Definition
| Works best in hypoxic tumors due to chemical necessity for reduction. It is a potent radiosensitizer |
|
|
Term
|
Definition
| best available therapy for use in combination with radiation therapy to attack hypoxic tumor cells, making ideal if you need to use less radiation because of limitation factors, such as in anal cancer |
|
|
